HRMY — Harmony Biosciences Holdings, Inc.

Harmony Biosciences Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Revenue: $239.5 million for Q3 2025, a 29% increase year-over-year.
• Cash Generation: $106 million in cash flow, with a total cash balance of $778 million as of September 30, 2025.
• Non-GAAP Adjusted Net Income: $63.5 million ($1.08 per diluted share), up from $57.3 million ($0.99 per diluted share) in Q3 2024.
• Patient Growth: Average of 8,100 patients on WAKIX, with a record increase of approximately 500 patients added in Q3.

2. Strategic Updates and Business Highlights

• WAKIX Performance: Strong demand attributed to its unique position as the only nonscheduled treatment option for narcolepsy, supported by high brand awareness and broad payer coverage.
• Pipeline Development:
  • IND submitted for pitolisant HD, with plans to initiate two Phase III trials by year-end (one in narcolepsy and one in idiopathic hypersomnia).
  • Continued progress on EPX-100 for Dravet syndrome and Lennox-Gastaut syndrome, with data presentations expected at the American Epilepsy Society meeting in December.
• Business Development: Harmony remains focused on strategic acquisitions to enhance its pipeline and product portfolio, despite recent setbacks with ZYN002 in Fragile X syndrome.

3. Forward Guidance and Outlook

• Revenue Guidance: Raised from $820 million to a new range of $845 million to $865 million for the full year 2025.
• Blockbuster Potential: WAKIX is on track to achieve blockbuster status (over $1 billion in annual revenue) in narcolepsy alone, with expectations of continued growth into 2026.

4. Bad News, Challenges, or Points of Concern

• ZYN002 Setback: The Phase III RECONNECT study for Fragile X syndrome did not meet its primary endpoint due to a higher-than-expected placebo response, leading to a pause in the 22q deletion syndrome trial.
• Competitive Pressures: The introduction of new treatments, such as orexin agonists, may impact WAKIX's market position, although management remains confident in WAKIX's differentiation and established presence.
• Inventory Fluctuations: A slight increase in trade inventory during Q3 may affect Q4 sales, making it challenging to predict exact revenue outcomes.

5. Notable Q&A Insights

• Patient Growth Drivers: The increase in patient adds is attributed to both new prescribers and deeper penetration among existing writers, with a stable distribution of NT1 (45%) and NT2 (55%) patients.
• Switching Patients: The potential for patients currently on WAKIX to switch to pitolisant HD is based on their residual symptoms and the promise of improved efficacy without new safety concerns.
• Future Pipeline Confidence: Despite recent setbacks, management expressed strong conviction in the remaining pipeline programs, emphasizing the distinct endpoints and checks in place to manage placebo responses in ongoing trials.

Overall, Harmony Biosciences reported a robust Q3 2025, marked by significant revenue growth and patient additions, while navigating challenges in its pipeline and competitive landscape. The company remains optimistic about its future prospects and strategic initiatives.